CA2102447A1 - Cyclopeptides - Google Patents

Cyclopeptides

Info

Publication number
CA2102447A1
CA2102447A1 CA002102447A CA2102447A CA2102447A1 CA 2102447 A1 CA2102447 A1 CA 2102447A1 CA 002102447 A CA002102447 A CA 002102447A CA 2102447 A CA2102447 A CA 2102447A CA 2102447 A1 CA2102447 A1 CA 2102447A1
Authority
CA
Canada
Prior art keywords
asp
gly
arg
ala
cyclopeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002102447A
Other languages
French (fr)
Other versions
CA2102447C (en
Inventor
Alfred Jonczyk
Gunter Holzemann
Brunhilde Felding-Habermann
Friedrich Rippmann
Guido Melzer
Beate Diefenbach
Horst Kessler
Roland Haubner
Jochen Wermuth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2102447A1 publication Critical patent/CA2102447A1/en
Application granted granted Critical
Publication of CA2102447C publication Critical patent/CA2102447C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/52—Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to novel cyclopeptides of the formula I cyclo-(A-B-C-D-Arg) I in which A and B are each independently of one another Ala, Asn, Asp, Arg, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val, C is Asp or Asp (O-C1-4-alkyl) and D is Gly or Ala, at least two of the amino acid radicals stated being present in the D-form, and their salts. These compounds act as integrin inhibitors and can be used in particular for the prophylaxis and treatment of disorders of the circulation and in tumour therapy.
CA002102447A 1992-11-06 1993-11-04 Cyclopeptides Expired - Lifetime CA2102447C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4237456A DE4237456A1 (en) 1992-11-06 1992-11-06 cyclopeptides
DEP4237456.1 1992-11-06

Publications (2)

Publication Number Publication Date
CA2102447A1 true CA2102447A1 (en) 1994-05-07
CA2102447C CA2102447C (en) 2007-04-10

Family

ID=6472232

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002102447A Expired - Lifetime CA2102447C (en) 1992-11-06 1993-11-04 Cyclopeptides

Country Status (21)

Country Link
EP (1) EP0596350B1 (en)
JP (1) JP3681764B2 (en)
KR (1) KR100238894B1 (en)
CN (1) CN1038751C (en)
AT (1) ATE154037T1 (en)
AU (1) AU666586B2 (en)
CA (1) CA2102447C (en)
CZ (1) CZ286170B6 (en)
DE (2) DE4237456A1 (en)
DK (1) DK0596350T3 (en)
ES (1) ES2105041T3 (en)
GR (1) GR3024550T3 (en)
HU (1) HU215600B (en)
MX (1) MX9306885A (en)
NO (1) NO309864B1 (en)
PL (1) PL177772B1 (en)
RU (1) RU2129563C1 (en)
SK (1) SK280597B6 (en)
TW (1) TW340849B (en)
UA (1) UA43822C2 (en)
ZA (1) ZA938281B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11975041B2 (en) * 2017-11-20 2024-05-07 Novmetapharma Co., Ltd. Composition comprising CHP (cyclo-his pro) for preventing, improving or treating of bone loss related disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816449A (en) * 1984-08-09 1989-03-28 Immunetech Pharmaceuticals Immunotherapeutic anti-inflammatory peptide agents

Also Published As

Publication number Publication date
PL177772B1 (en) 2000-01-31
SK280597B6 (en) 2000-04-10
EP0596350A1 (en) 1994-05-11
RU2129563C1 (en) 1999-04-27
PL300935A1 (en) 1994-05-16
JP3681764B2 (en) 2005-08-10
KR940011479A (en) 1994-06-21
TW340849B (en) 1998-09-21
ES2105041T3 (en) 1997-10-16
DE4237456A1 (en) 1994-05-11
ATE154037T1 (en) 1997-06-15
NO934003D0 (en) 1993-11-05
GR3024550T3 (en) 1997-12-31
EP0596350B1 (en) 1997-06-04
UA43822C2 (en) 2002-01-15
AU5039993A (en) 1994-05-19
CZ286170B6 (en) 2000-02-16
NO309864B1 (en) 2001-04-09
SK121793A3 (en) 1995-06-07
HU215600B (en) 1999-01-28
AU666586B2 (en) 1996-02-15
CA2102447C (en) 2007-04-10
HUT68321A (en) 1995-06-28
DK0596350T3 (en) 1997-12-29
CN1093090A (en) 1994-10-05
KR100238894B1 (en) 2000-01-15
CZ235293A3 (en) 1994-07-13
CN1038751C (en) 1998-06-17
NO934003L (en) 1994-05-09
DE59306654D1 (en) 1997-07-10
MX9306885A (en) 1995-01-31
ZA938281B (en) 1994-06-07
JPH0892282A (en) 1996-04-09

Similar Documents

Publication Publication Date Title
CA2120303A1 (en) Cyclic adhesion inhibitors
NZ248377A (en) Use of interleukin-1 beta protease and interleukin-1 beta protease inhibitors
IL104314A0 (en) Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them
HK1160778A1 (en) Pharmaceutical composition comprising an analgesic peptide
CA2148194A1 (en) Cyclopeptides of the formula i
CA2143610A1 (en) Use of norastemizole for the treatment of allergic disorders
NO941151L (en) Linear adhesion inhibitors
CA2002924A1 (en) Anti-Thrombins
GR3015888T3 (en) Peptides for treatment.
CA2102606A1 (en) Compositions for the treatment of chronic fatigue syndrome
HUP0003357A2 (en) Cyclic azapeptides with angiogenic effect, pharmaceutical compositions comprising them, processes for producing thereof and their use
CA2096933A1 (en) Compounds and compositions which inhibit bone resorption
CA2102447A1 (en) Cyclopeptides
DE3569541D1 (en) Pharmacologically active peptides
CA2290739A1 (en) New bpc peptide salts with organo-protective activity, the process for their preparation and their use in therapy
HK1013622A1 (en) Pharmaceutical lysine-containing polypeptide compositions and the use thereof
RU95120588A (en) CYCLOGEXAEPEPTIDES, THEIR MIXTURES, METHOD FOR PRODUCING AND USING THEM
EP0248231A3 (en) Pharmacologically active peptides
NZ268039A (en) Use of efaroxan in treating parkinson's disease
KR950704358A (en) Cathepsin L specific inhibitory polypeptide
IL115825A0 (en) Therapeutic protein
RU93050068A (en) CYCLOPEPTIDES, METHOD OF THEIR PRODUCTION, PHARMACEUTICAL COMPOSITIONS AND METHOD OF THEIR PRODUCTION, METHOD OF TREATMENT
EP0621789A4 (en) Pharmaceutical pentapeptide compositions and methods of use thereof.
RU94036002A (en) Protease inhibitor, dna, vector, cell, method of inhibitor preparing, pharmaceutical composition
AU2002238532A1 (en) Tripeptide derivatives for the treatment of postlesional diseases of the nervous system

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20131104